ArticleCancer medicine2026
Survival Outcomes and Late Toxicity of Postoperative Radiotherapy in Patients With Adenoid Cystic Carcinoma of the External Auditory Canal.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAdenoid cystic carcinoma (ACC) of the external auditory canal (EAC) is an extremely rare head and neck malignancy. The study aimed to investigate the long-term outcomes and late toxicity of postoperative radiotherapy (PORT) for patients with EAC ACC.
methodsBetween 2004 and 2021, 60 patients with EAC ACC were retrospectively analyzed. The overall survival (OS), local recurrence-free survival (LRFS), nodal recurrence-free survival (NRFS), and distant metastasis-free survival (DMFS) were calculated by the Kaplan-Meier method.
resultsWith a median follow-up of 110.3 months, the 10-year OS, LRFS, NRFS, and DMFS rates were 84.2%, 79.5%, 96.2%, and 59.9% after PORT, respectively. Eleven patients (18.3%) experienced local failure, 2 (3.3%) had regional failure, and 23 (38.3%) had distant metastasis (DM). Multivariate analysis showed that the advanced T stage (T3-4) was an independent risk factor for OS (p = 0.019) and DMFS (p = 0.006). Late toxicities were assessed in 45 patients. Among them, 73.3% (33/45) of patients experienced grade 3-4 ipsilateral hearing loss after surgery. Furthermore, xerostomia (31.1%, 14/45) and radiation-related caries (26.7%, 12/45) were the most common late toxicities of radiotherapy-related. For clinical N0 (cN0) patients (n = 58), the ipsilateral elective neck irradiation (ENI) did not improve the OS (p = 0.929), NRFS (p = 0.317), or DMFS (p = 0.778) for the advanced patients (T3-4).
conclusionsSurgery plus PORT is associated with excellent long-term survival with tolerable late toxicity for EAC ACC patients. ENI of cN0 patients shows no survival benefit, which suggests that the omission of ENI is reasonable to reduce radiation-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.